NEW YORK, July 22 — Fenfluramine is back on the American market, a comeback twenty-three years in the making. The same drug that triggered one of the biggest pharmaceutical scandals of the 1990s was reintroduced in the United States and the European Union in 2020, rebranded as a treatment for two rare pediatric epilepsy syndromes. The catch: the cardiovascular toxicity that forced its withdrawal has not been eliminated.
It is simply managed by a federal lockdown known as a Risk Evaluation and Mitigation Strategy program. The claim of a second chance for a notorious appetite suppressant sounds like a neat pivot.
But on closer reading, the mechanics of that return reveal a drug whose fundamental risk profile has not changed. Fenfluramine was withdrawn from the U.S. market in 1997 after it was linked to valvular heart disease and pulmonary arterial hypertension. Those same conditions are the subject of a boxed warning on its current label.
The REMS program that governs its use today requires certified prescribers, certified pharmacies, mandatory patient enrollment, and echocardiograms at regular intervals. This is not a cleaned-up molecule.
It is a tightly controlled distribution channel designed to contain the predictable consequences of the drug’s original toxicity.
From diet pill to disaster
Fenfluramine began life as a conventional pharmaceutical success. Developed in the early 1960s as a serotonergic appetite suppressant, it was approved in France in 1963 and reached the U.S. market in 1973 under the brand name Pondimin. It gained widespread notoriety in the 1990s when it was combined with phentermine in the wildly popular weight-loss regimen known as fen-phen.
That combination sold in enormous volumes before reports began surfacing linking it to heart valve damage and a rare but lethal lung condition. By the time the manufacturer pulled it, the liability was already catastrophic.
Follow the money: the fen-phen episode produced one of the largest mass-tort settlements in American history. The drug’s second act, by contrast, is aimed at a tiny patient population — children aged two and older with Dravet syndrome or Lennox–Gastaut syndrome, severe forms of epilepsy that often resist standard treatments. The potential for profit is far smaller, and the regulatory barriers are far higher.
But the profit structure matters less than the fact that the drug itself remains, chemically, a phenethylamine and an amphetamine. It acts as a serotonin and norepinephrine releasing agent, an agonist of serotonin 5-HT2 receptors, and a positive modulator of sigma σ1 receptors.
Why that combination reduces seizures is unknown. The mechanism may involve serotonin and sigma receptors, but that is a hypothesis, not an explanation.
A controlled substance un-controlled
One detail stands out in the drug’s regulatory history. Fenfluramine was once classified as a Schedule IV controlled substance in the United States. That classification was removed by a rule issued on December 23, 2022 — a quiet administrative move that lifts the federal scheduling restrictions that apply to other appetite-suppressant amphetamines.
The rationale is presumably that the drug’s abuse potential in the severely ill pediatric population is low. But the removal of Schedule IV status also means that the drug is no longer tracked under the same federal narcotics framework.
That may simplify prescribing, but it does not change the chemistry of a molecule that the source material describes as an amphetamine. Common adverse reactions now include decreased appetite, drowsiness, sedation, diarrhea, constipation, abnormal echocardiogram, fatigue, ataxia, balance disorder, gait disturbance, increased blood pressure, drooling, fever, upper respiratory infection, vomiting, weight loss, falls, and status epilepticus. That is not a side-effect profile that would pass muster for a lifestyle drug.
In the context of catastrophic epilepsy, regulators judged the risk-benefit calculus acceptable — but only with the REMS architecture in place.
What comes next
Research is already exploring fenfluramine for Sunflower syndrome, a rare form of epilepsy defined by hand-flapping seizures triggered by light. Whether the drug’s second life extends beyond the two approved syndromes depends partly on that clinical data and partly on whether the REMS model can be scaled. The underlying toxicity has not gone anywhere.
The question is how many patients and how many indications the regulatory apparatus can safely absorb before the boxed warning becomes more than theoretical.
Sources
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Fenfluramine: From Fen-Phen scandal to seizure drug”, “description”: “NEW YORK, July 22 — Fenfluramine is back on the American market, a comeback twenty-three years in the making. The same drug that triggered one…”, “datePublished”: “2026-07-22T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Beatrice Ferrari”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}, “citation”: [{“@type”: “CreativeWork”, “url”: “https://en.wikipedia.org/wiki/Fenfluramine”}]}
